Molecular Partners to Present at Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz will present at key healthcare investor events in January 2022. Key conferences include the H.C. Wainwright BioConnect 2022 on January 10, the JP Morgan 40th Annual Virtual Healthcare Conference on January 12, and the Baader Helvea Swiss Equities Conference on the same day. Additionally, Amstutz will participate in the Octavian Seminar 2022 on January 14. All presentations will be available for viewing on the Molecular Partners website.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022.

Conference Presentation Details:

H.C. Wainwright BioConnect 2022 Conference

• Monday, January 10, 2022 at 12:00 pm ET (6:00 pm CET); on-demand on January 10-13, 2022
  

JP Morgan 40^th Annual Virtual Healthcare Conference

• Wednesday, January 12, 2022 at 7:30 am ET (1:30 pm CET)
  

Baader Helvea Swiss Equities Conference

• Wednesday, January 12, 2022 at 10:30 am ET (4:30 pm CET)
  

Conference Participation Details:

The Octavian Seminar 2022

• Friday, January 14, 2022
  

All webcasted presentations will be made available on the Molecular Partners website.

About Molecular Partners AG  

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs 

FAQ

What events will Molecular Partners AG participate in January 2022?

Molecular Partners AG will participate in the H.C. Wainwright BioConnect 2022 on January 10, the JP Morgan 40th Annual Virtual Healthcare Conference, and the Baader Helvea Swiss Equities Conference on January 12, and the Octavian Seminar 2022 on January 14.

When is the H.C. Wainwright BioConnect 2022 Conference?

The H.C. Wainwright BioConnect 2022 Conference is scheduled for January 10, 2022, at 12:00 pm ET.

What time will Patrick Amstutz present at the JP Morgan Conference?

Patrick Amstutz will present at the JP Morgan 40th Annual Virtual Healthcare Conference on January 12, 2022, at 7:30 am ET.

Where can I find the webcasts of the presentations by Molecular Partners AG?

The webcasts of the presentations will be available on the Molecular Partners website.

What is the focus of Molecular Partners AG's research?

Molecular Partners AG focuses on developing DARPin therapeutics, a new class of protein drugs targeted at ophthalmology, oncology, and infectious diseases.